ArticleBMC complementary medicine and therapies2026
A novel green synthesis of gold nanoparticles using Syrian bee bread extract: phytochemical analysis, characterization, antimicrobial activity and biocompatibility.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the bioactive composition of Syrian bee bread (SBB) and its application in the green synthesis of gold nanoparticles (AuNPs). For the first time, bee bread was utilized for the synthesis of AuNPs. The SBB extract exhibited high levels of phenolic and flavonoid compounds. High-performance liquid chromatography (HPLC) identified key phenolic flavonoid, and sugar components, while Gas chromatography-mass spectrometry (GC-MS) revealed various bioactive constituents. The synthesis was optimized at pH 9.5, gold salt concentration of 2 mM, SBB extract 1%, and room temperature, yielding small, stable and well-dispersed AuNPs with Z-average of 46.38 ± 6.12 nm, polydispersity index (PDI) of 0.235 ± 0.002, and ζ-potential of − 29.7 mV according to Dynamic Light Scattering (DLS). Ultraviolet-visible spectroscopy (UV-Vis) showed a Localized surface plasmon resonance (LSPR) peak at 524 nm. Atomic Force Microscopy (AFM) and Field Emission Scanning Electron Microscopy (FESEM) confirmed spherical nanoparticles, with sizes of ~ 33 nm and ~ 28.69 nm, respectively. The SBB-AuNPs displayed antimicrobial activity against Pseudomonas aeruginosa, Escherichia coli, Klebsiella Spp., and Candida albicans, with inhibition zones ranging from 18 to 27 mm. Importantly, no cytotoxic effects were observed in normal fibroblast cells at concentrations below 100 µg/mL indicating promising biocompatibility. This novel approach yields small, stable, and bioactive nanoparticles with potent antimicrobial properties and high biocompatibility, representing a significant improvement over other bee product-based methods. These findings highlight the potential biomedical applications of SBB-AuNPs, including their incorporation into topical creams or ointments for the prevention and treatment of skin infections, wound-healing formulations, and as antimicrobial agents in medical devices or protective coatings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.